Stock DGNS PT DIAGNOS LABORATORIUM UTAMA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Diagnos Laboratorium Utama Tbk

Equities

DGNS

ID1000158702

Healthcare Facilities & Services

End-of-day quote INDONESIA S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
206 IDR -4.63% Intraday chart for PT Diagnos Laboratorium Utama Tbk -1.90% -16.26%
16/05 PT Diagnos Laboratorium Utama Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04/03 PT Diagnos Laboratorium Utama Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 9,31,250 3,05,000 3,07,500
Enterprise Value (EV) 1 8,92,275 2,87,726 3,50,273
P/E ratio 14.4 x 24.1 x -22.5 x
Yield - - -
Capitalization / Revenue 3.08 x 1.58 x 2.11 x
EV / Revenue 2.95 x 1.49 x 2.4 x
EV / EBITDA 10.4 x 11.6 x -97.2 x
EV / FCF -30.5 x -19.4 x -19.5 x
FCF Yield -3.28% -5.14% -5.13%
Price to Book 4.61 x 1.45 x 1.57 x
Nbr of stocks (in thousands) 12,50,000 12,50,000 12,50,000
Reference price 2 745.0 244.0 246.0
Announcement Date 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 38,553 51,338 1,83,171 3,02,182 1,92,886 1,45,696
EBITDA 1 12,827 14,628 69,043 86,042 24,834 -3,604
EBIT 1 12,418 13,174 66,986 81,227 15,439 -15,151
Operating Margin 32.21% 25.66% 36.57% 26.88% 8% -10.4%
Earnings before Tax (EBT) 1 12,228 12,643 66,975 83,279 17,333 -13,573
Net income 1 9,265 9,275 52,687 64,304 12,665 -13,656
Net margin 24.03% 18.07% 28.76% 21.28% 6.57% -9.37%
EPS 2 196.6 30.88 52.69 51.84 10.13 -10.92
Free Cash Flow 1 8,188 5,223 -17,491 -29,272 -14,799 -17,955
FCF margin 21.24% 10.17% -9.55% -9.69% -7.67% -12.32%
FCF Conversion (EBITDA) 63.84% 35.71% - - - -
FCF Conversion (Net income) 88.38% 56.32% - - - -
Dividend per Share - - - - - -
Announcement Date 14/12/20 14/12/20 01/04/21 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 1,584 - - - 42,773
Net Cash position 1 1,537 - 14,630 38,975 17,274 -
Leverage (Debt/EBITDA) - 0.1083 x - - - -11.87 x
Free Cash Flow 1 8,188 5,223 -17,491 -29,272 -14,799 -17,955
ROE (net income / shareholders' equity) 112% 31.1% 72.4% 42.7% 6.14% -6.73%
ROA (Net income/ Total Assets) 47.1% 19.7% 43.7% 27.1% 4% -3.7%
Assets 1 19,653 47,118 1,20,684 2,37,215 3,16,274 3,68,757
Book Value Per Share 2 332.0 46.50 99.10 161.0 168.0 156.0
Cash Flow per Share 2 38.40 1.390 16.50 35.80 22.40 8.200
Capex 1 3,837 2,782 5,864 67,841 34,853 38,324
Capex / Sales 9.95% 5.42% 3.2% 22.45% 18.07% 26.3%
Announcement Date 14/12/20 14/12/20 01/04/21 05/04/22 30/03/23 04/03/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
PT DIAGNOS LABORATORIUM UTAMA TBK Stock PT Diagnos Laboratorium Utama Tbk
-16.26% 16.49M
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-18.02% 8.42B
RADNET, INC. Stock RadNet, Inc.
+70.89% 4.35B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+7.88% 2.74B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-56.54% 1.78B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
-15.27% 1.7B
FLEURY S.A. Stock Fleury S.A.
-16.35% 1.47B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+17.87% 1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-49.60% 1.03B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-21.78% 927M
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. DGNS Stock
  4. Financials PT Diagnos Laboratorium Utama Tbk